Company / CIK 0001869105
BridgeBio Oncology Therapeutics, Inc.
- Ticker
- BBOT
- Size, estimated from filings
- Small cap ($300M – $2B)
- Insiders on file
- 14
- Federal contracts on record
- none matched
- Lobbying filings on record
- none matched
- SEC filings
- EDGAR ↗
- Latest trade on record
- October 1, 2026
BridgeBio Oncology Therapeutics, Inc. (BBOT) has 14 insiders on file who disclosed 36 transactions in the last 12 months (0 open-market buys, 12 sales, about $55K at reported prices). No federal contract award that started in the last 180 days was found for a recipient with exactly this name; no lobbying filing names it as client this year.
BridgeBio Oncology Therapeutics, Inc. in charts
Who is trading this stock
Which people account for the buying and selling over the last 12 months?
5 people account for the disclosed buying and selling in BridgeBio Oncology Therapeutics, Inc. over the last 12 months; the most active is Beltran Pedro with $22K.
Insiders
| Name | Role | Rows | Bought | Sold | Last filed |
|---|---|---|---|---|---|
| Ben Yong | Chief Med & Dev Officer | 5 | 0 | 3 | October 5, 2026 |
| Beltran Pedro | Chief Scientific Officer | 6 | 0 | 3 | October 5, 2026 |
| Elmelech Idan | COO & Principal Financial Ofcr | 3 | 0 | 2 | October 5, 2026 |
| Cobo Marc | Principal Accounting Officer | 5 | 0 | 3 | October 5, 2026 |
| Kumar Neil | Chief Executive Officer | 1 | 0 | 0 | September 21, 2026 |
| Chen Bihua | Director | 5 | 0 | 0 | July 6, 2026 |
| MCCORMICK FRANK | Director | 1 | 0 | 0 | June 24, 2026 |
| Lebowitz Peter F | Director | 2 | 0 | 0 | June 18, 2026 |
| Bauer Jake | Director | 1 | 0 | 0 | June 18, 2026 |
| Kelleher Raymond J. | Director | 1 | 0 | 0 | June 18, 2026 |
| Tipirneni Praveen P. | Director | 1 | 0 | 0 | June 18, 2026 |
| Mehra Uneek | Chief Financial Officer | 3 | 0 | 1 | May 5, 2026 |
| Wallace Eli M. | Chief Executive Officer | 3 | 0 | 0 | January 5, 2026 |
| BridgeBio Pharma LLC | Insider | 1 | 0 | 0 | October 16, 2025 |
Rows are this company's Form 4 rows for each person. "Bought" and "sold" count open-market purchases (code P) and sales only. More in insider buying and insider selling.
Insider transactions
| Filer | Security | Side | Trade date | Disclosed | Lag | Shares | Price | Value | Flags | Source | Share |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cobo Marc | BBOT | Sell F | October 1, 2026 | October 5, 2026 | 4d | 126 | $4 | $496 | Form 4 ↗ | ||
| Elmelech Idan | BBOT | Sell F | October 1, 2026 | October 5, 2026 | 4d | 343 | $4 | $1,351 | Form 4 ↗ | ||
| Beltran Pedro | BBOT | Sell F | October 1, 2026 | October 5, 2026 | 4d | 1,047 | $4 | $4,125 | Form 4 ↗ | ||
| Ben Yong | BBOT | Sell F | October 1, 2026 | October 5, 2026 | 4d | 1,047 | $4 | $4,125 | Form 4 ↗ | ||
| Cobo Marc | BBOT | Other A | September 10, 2026 | September 14, 2026 | 4d | 43,700 | — | — | derivative | Form 4 ↗ | |
| Cobo Marc | BBOT | Sell F | September 10, 2026 | September 14, 2026 | 4d | 203 | $6 | $1,121 | Form 4 ↗ | ||
| Cobo Marc | BBOT | Other A | September 10, 2026 | September 14, 2026 | 4d | 9,038 | — | — | Form 4 ↗ | ||
| Cobo Marc | BBOT | Sell F | July 1, 2026 | July 6, 2026 | 5d | 125 | $8 | $975 | late | Form 4 ↗ | |
| Elmelech Idan | BBOT | Sell F | July 1, 2026 | July 6, 2026 | 5d | 343 | $8 | $2,675 | late | Form 4 ↗ | |
| Ben Yong | BBOT | Sell F | July 1, 2026 | July 6, 2026 | 5d | 1,047 | $8 | $8,167 | late | Form 4 ↗ | |
| Beltran Pedro | BBOT | Sell F | July 1, 2026 | July 6, 2026 | 5d | 1,047 | $8 | $8,167 | late | Form 4 ↗ | |
| Chen Bihua | BBOT | Other J | July 1, 2026 | July 6, 2026 | 5d | 130,865 | — | — | lateindirect | Form 4 ↗ | |
| Chen Bihua | BBOT | Other J | July 1, 2026 | July 6, 2026 | 5d | 1,704,862 | — | — | lateindirect | Form 4 ↗ | |
| Chen Bihua | BBOT | Other J | July 1, 2026 | July 6, 2026 | 5d | 2,692,459 | — | — | lateindirect | Form 4 ↗ | |
| Chen Bihua | BBOT | Other J | July 1, 2026 | July 6, 2026 | 5d | 4,528,186 | — | — | lateindirect | Form 4 ↗ | |
| Tipirneni Praveen P. | BBOT | Other A | June 16, 2026 | June 18, 2026 | 2d | 31,675 | — | — | derivative | Form 4 ↗ | |
| MCCORMICK FRANK | BBOT | Other A | June 16, 2026 | June 18, 2026 | 2d | 31,675 | — | — | derivative | Form 4 ↗ | |
| Lebowitz Peter F | BBOT | Other A | June 16, 2026 | June 18, 2026 | 2d | 7,289 | — | — | derivative | Form 4 ↗ | |
| Kelleher Raymond J. | BBOT | Other A | June 16, 2026 | June 18, 2026 | 2d | 31,675 | — | — | derivative | Form 4 ↗ | |
| Chen Bihua | BBOT | Other A | June 16, 2026 | June 18, 2026 | 2d | 31,675 | — | — | derivative | Form 4 ↗ | |
| Bauer Jake | BBOT | Other A | June 16, 2026 | June 18, 2026 | 2d | 31,675 | — | — | derivative | Form 4 ↗ | |
| Kumar Neil | BBOT | Other A | June 16, 2026 | June 18, 2026 | 2d | 31,675 | — | — | derivative | Form 4 ↗ | |
| Elmelech Idan | BBOT | Other A | May 10, 2026 | May 12, 2026 | 2d | 758,222 | — | — | derivative | Form 4 ↗ | |
| Beltran Pedro | BBOT | Other A | May 10, 2026 | May 12, 2026 | 2d | 1,103,837 | — | — | derivative | Form 4 ↗ | |
| Ben Yong | BBOT | Sell F | April 1, 2026 | May 5, 2026 | 34d | 1,047 | $9 | $9,454 | late | Form 4 ↗ | |
| Beltran Pedro | BBOT | Sell F | April 1, 2026 | May 5, 2026 | 34d | 1,047 | $9 | $9,454 | late | Form 4 ↗ | |
| Mehra Uneek | BBOT | Sell F | April 1, 2026 | May 5, 2026 | 34d | 524 | $9 | $4,732 | late | Form 4 ↗ | |
| Lebowitz Peter F | BBOT | Other A | March 24, 2026 | March 26, 2026 | 2d | 63,350 | — | — | derivative | Form 4 ↗ | |
| Mehra Uneek | BBOT | Other A | March 10, 2026 | March 12, 2026 | 2d | 105,000 | — | — | derivative | Form 4 ↗ | |
| Mehra Uneek | BBOT | Other A | March 10, 2026 | March 12, 2026 | 2d | 23,330 | — | — | Form 4 ↗ | ||
| Beltran Pedro | BBOT | Other A | March 10, 2026 | March 12, 2026 | 2d | 210,000 | — | — | derivative | Form 4 ↗ | |
| Beltran Pedro | BBOT | Other A | March 10, 2026 | March 12, 2026 | 2d | 46,670 | — | — | Form 4 ↗ | ||
| Ben Yong | BBOT | Other A | March 10, 2026 | March 12, 2026 | 2d | 210,000 | — | — | derivative | Form 4 ↗ | |
| Ben Yong | BBOT | Other A | March 10, 2026 | March 12, 2026 | 2d | 46,670 | — | — | Form 4 ↗ | ||
| Wallace Eli M. | BBOT | Other A | January 1, 2026 | January 5, 2026 | 4d | 1,114,400 | — | — | derivative | Form 4 ↗ | |
| Wallace Eli M. | BBOT | Option / conversion D | December 10, 2025 | December 12, 2025 | 2d | 1,114,400 | — | — | derivative | Form 4 ↗ | |
| BridgeBio Pharma LLC | BBOT | Other J | October 10, 2025 | October 16, 2025 | 6d | 784,720 | — | — | late | Form 4 ↗ | |
| Wallace Eli M. | BBOT | Other A | October 2, 2025 | October 6, 2025 | 4d | 1,614,400 | — | — | derivative | Form 4 ↗ |
Federal contracts (USAspending, awards started in the last 180 days)
No contract award starting in the last 180 days was found for a recipient named exactly "BridgeBio Oncology Therapeutics, Inc.". Subsidiaries and differently-spelled recipients are not matched — search contracts.
Lobbying (Senate LDA, as client)
No LDA filing posted since October 2025 names "BridgeBio Oncology Therapeutics, Inc." as the client. Filings under a subsidiary or trade-association name are not matched — search lobbying.
Related companies
Companies whose stock was traded by the same people who traded BBOT, by number of filers in common. It shows overlap in public filings and nothing else.
- BridgeBio Pharma, Inc. BBIO 2 filers in common
- Immunovant, Inc. IMVT 1 filer in common
Guides for this page
- What is SEC Form 4? Who files: officers, directors and owners of more than 10% of a class of the company's shares.
- Insider buying vs insider selling Selling outweighs buying by a wide margin in normal times.
- What disclosure data cannot tell you Filings are late by design: up to 45 days for Congress, two business days for insiders.
Sources and method
| Source | Filings | Rows | First filed | Newest filed | Read the originals |
|---|---|---|---|---|---|
| SEC EDGAR, Form 4 | 30 | 38 | October 6, 2025 | October 5, 2026 | Form 4 list on EDGAR |
Site built October 22, 2026. Every row in the tables above links to its own filing. To quote a figure, use the Cite button at the top of the page; see how to cite and reuse.
Insiders and their transactions come from SEC EDGAR Form 4 filings for this issuer. Contracts and lobbying are matched by exact normalized name (suffixes like Inc./Corp. ignored) to USAspending recipients and LDA clients — a conservative match that misses subsidiaries on purpose. See methodology and corrections.
Not investment advice. Public records shown as filed; no recommendation is made or implied.